17p11.2 microduplication syndrome

17p11.2 microduplication syndrome, also known as Potocki-Lupski syndrome (PTLS), is a rare genetic condition caused by a duplication of a small segment of the short arm of chromosome 17 (17p11.2). This region includes the RAI1 gene, which is considered the critical gene responsible for many of the syndrome's features. The duplication is the reciprocal event of the deletion that causes Smith-Magenis syndrome. PTLS affects multiple body systems, including the nervous system, cardiovascular system, and musculoskeletal system. Key clinical features include infantile hypotonia (low muscle tone), failure to thrive and feeding difficulties in infancy, intellectual disability that is typically mild to borderline, speech and language delays, behavioral difficulties including features of autism spectrum disorder, and congenital heart defects (present in approximately 40% of patients). Motor developmental milestones are often delayed. Many individuals exhibit sleep-disordered breathing, including obstructive and central sleep apnea. Facial features may be mildly distinctive, including a triangular face, widely spaced eyes, and a broad forehead, though dysmorphic features can be subtle. There is no cure for Potocki-Lupski syndrome, and management is supportive and symptom-based. Early intervention services including speech therapy, occupational therapy, physical therapy, and behavioral therapy are recommended. Cardiac anomalies may require surgical correction. Regular monitoring for sleep apnea and developmental progress is important. With appropriate support, many individuals make meaningful developmental gains over time, and the prognosis is generally more favorable than in Smith-Magenis syndrome.

Common questions about 17p11.2 microduplication syndrome